Efficacy of single-dose evolocumab injection in early-phase acute myocardial infarction: a retrospective single-center study
Yongcheol Kim, Ji Woong Roh, Oh-Hyun Lee, Seok-Jae Heo, Eui Im, Deok-Kyu Cho, Byeong-Keuk Kim
Korean J Intern Med. 2024;39(5):793-800. Published online 2024 Jun 24 DOI: https://doi.org/10.3904/kjim.2024.080
Citations to this article as recorded by 
Impact of early initiation of PCSK9I monoclonal antibodies after acute coronary syndrome
Pravin K. Goel, Aditya Kapoor, Kala Jeetender Jain, Rajesh Thachathodiyl, Vikas Reddy, Vivek Guleria, Neeraj Bhalla, Shyam Sasidharan
Indian Heart Journal.2026;[Epub] CrossRef
Short-term effects of PCSK-9 inhibitors on percutaneous coronary intervention in patients with acute coronary syndrome
Dong Hyun Gim, In Young Choi, Young-Jae Ki, Hyun Kuk Kim, Sung Soo Kim, Keun-Ho Park, Heesang Song, Dong-Hyun Choi
The Korean Journal of Internal Medicine.2025; 40(3): 438. CrossRef
Real-World Safety and Effectiveness of Evolocumab in Korean Patients with Atherosclerotic Cardiovascular Disease or Familial Hypercholesterolemia: A Post-Marketing Surveillance Study
Donggyu Moon, Seung-Ho Hur, Sang-Rok Lee, Myung Ho Jeong, Kyung Hoon Cho, Osung Kwon, JinSeon Jeong, Ki Dong Yoo
Cardiology and Therapy.2025; 14(4): 619. CrossRef
Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in patients after percutaneous coronary intervention: a systematic review and meta-analysis
Zhantao Cao, Ningjing Chen, Jun Chen, Xuejing Xu, Zhanglu Zhang, Yunsu Wang
Frontiers in Cardiovascular Medicine.2025;[Epub] CrossRef
PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression
Maram H. Abduljabbar
Pharmaceuticals.2024; 17(12): 1581. CrossRef